HM Payson & Co’s Aerie Pharmaceuticals AERI Stock Holding History

HM Payson & Co’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,189	Closed	-$14K	–	1196
2021 Q3	$14K	Buy	+1,189	New	+$17.4K	﹤0.01%	798

Other funds holding AERI

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

HM Payson & Co's AERI Position: Q4 2021 in Review

HM Payson & Co sold out of Aerie Pharmaceuticals (AERI) in Q4 2021, closing a stake of 1,189 shares — an estimated $14K sold.

HM Payson & Co first reported a position in AERI in Q3 2021 and held it in 1 quarter. The position peaked at $14K in Q3 2021. 129 funds tracked by Wall St. Rank hold AERI as of Q4 2021.

HM Payson & Co reported no remaining Aerie Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
HM Payson & Co sold 1,189 Aerie Pharmaceuticals shares in Q4 2021, an estimated $14K.
HM Payson & Co first reported a position in Aerie Pharmaceuticals in Q3 2021 and held it in 1 quarter.
HM Payson & Co's Aerie Pharmaceuticals position peaked at $14K in Q3 2021.
129 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2021.

Based on HM Payson & Co's 13F filing for Q4 2021, filed 15 Feb 2022.